Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2023
December 2023, Vol 14, No 6
December 2023, Vol 14, No 6
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC
By
William King
ESMO
,
Lung Cancer
December 2023, Vol 14, No 6
Madrid, Spain—A perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab demonstrated a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant placebo in patients with resectable non–small cell lung cancer.
Read More
Fruzaqla FDA Approved for Relapsed Metastatic Colorectal Cancer
FDA Approvals, News & Updates
December 2023, Vol 14, No 6
On
November 8, 2023
, the FDA approved fruquintinib (Fruzaqla; Takeda Pharmaceuticals), an inhibitor of
VEGFR
-1
,
-2
, and
-3
, for the treatment of metastatic colorectal cancer (mCRC) in adults who received previous fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if
RAS
wild-type and medically appropriate, an anti-
EGFR
therapy. The FDA granted fruquintinib priority review for this indication.
Read More
AVBCC Keynote: The Path to Innovation in Oncology
By
Phoebe Starr
AVBCC 2023 Summit
December 2023, Vol 14, No 6
At the 13th Annual Association for Value Based Cancer Care Summit, held October 18-20, 2023, in New York City, Scott Gottlieb, MD, Former Commissioner of the FDA, gave the keynote lecture on how to foster innovation in oncology.
Read More
FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Metastatic or Recurrent Nasopharyngeal Carcinoma
FDA Approvals, News & Updates
December 2023, Vol 14, No 6
On
October 27, 2023
, the FDA approved toripalimab-tpzi (Loqtorzi; Coherus BioSciences), a PD-1 monoclonal antibody, in combination with cisplatin and gemcitabine chemotherapy, for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma, and as a single agent for adults with recurrent, unresectable, or metastatic nasopharyngeal carcinoma that progressed during or after treatment with a platinum-containing chemotherapy.
Read More
Do AI Chatbots Give Reliable Advice Regarding Cancer?
By
Anne Rowe
Healthcare Technology
December 2023, Vol 14, No 6
Artificial intelligence (AI) chatbots showed mixed results when it came to providing treatment strategies and direct-to-patient cancer advice for a variety of malignancies, according to 2 studies recently published in
JAMA Oncology
.
Read More
Keytruda Plus Chemotherapy Receives New FDA Approvals for Advanced Biliary Tract Cancer and 2 Forms of GEJ Adenocarcinoma
FDA Approvals, News & Updates
December 2023, Vol 14, No 6
On
November 16, 2023
, the FDA approved the use of pembrolizumab (Keytruda; Merck) with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adults with locally advanced unresectable or metastatic
HER2
-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Read More
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
By
Dawn Holcombe, MBA, FACMPE, ACHE
Editorial
December 2023, Vol 14, No 6
Beware of a new model that at least one, if not more, of the BlueCross BlueShield plans are offering to their self-insured employer customers as a way to compete with the alternate funding programs that have been pushed heavily onto those same employers in recent years.
Read More
Tibsovo FDA Approved for Patients with Relapsed Myelodysplastic Syndromes and IDH1 Mutation
FDA Approvals, News & Updates
December 2023, Vol 14, No 6
On
October 24, 2023
, the FDA approved ivosidenib (Tibsovo; Servier Pharmaceuticals), an oral tyrosine kinase inhibitor, for the treatment of relapsed or refractory myelodysplastic syndromes (MDS) in adults with a susceptible
IDH1
mutation, as detected by an FDA-approved test.
Read More
Addressing Challenges to Adoption of Value-Based Agreements
By
Phoebe Starr
AVBCC 2023 Summit
,
AVBCC
December 2023, Vol 14, No 6
In a session during the 13th Annual Summit of the Association for Value-Based Cancer Care, held October 18-20, 2023, in New York City, Linde Wilson, MBA, Managing Partner, HealthQuest Advisors, discussed the ongoing challenges related to the development and implementation of value-based agreements.
Read More
Opdivo Now Approved for Adjuvant Treatment of Stage IIB/C Melanoma
FDA Approvals, News & Updates
December 2023, Vol 14, No 6
On
October 13, 2023
, the FDA approved a new indication for nivolumab (Opdivo; Bristol-Myers Squibb), a PD-1 inhibitor, for the adjuvant treatment of completely resected stage IIB/C melanoma in patients aged ≥12 years. The FDA granted this application an orphan drug designation.
Read More
Page 1 of 2
1
2
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma